Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression

NCT01875367 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.

NCT NCT01875367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01875367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression
Lead sponsor
Spanish Breast Cancer Research Group
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2013
Completion date
April 30, 2018
Enrollment
166 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer